Elmwood Park, New Jersey, Nov 16: Glenmark Pharmaceuticals Inc., today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA®1 tablets.
According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million.
“The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States,” said Marc Kikuchi, President & Business Head, North America. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers.”

